Brentuximab vedotin (solution)

• CAT Number: I040377
• CAS Number: 914088-09-8
• Purity: ≥95%

Brentuximab vedotin(CAT: I040377) is an FDA-approved antibody-drug conjugate (ADC) designed for targeted cancer therapy, particularly Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL). It combines a chimeric anti-CD30 monoclonal antibody with monomethyl auristatin E (MMAE), a potent microtubule-disrupting agent. Upon binding to CD30-expressing cells, the complex is internalized, and MMAE is released to induce cell cycle arrest and apoptosis. Brentuximab vedotin demonstrates high specificity and cytotoxicity with reduced systemic toxicity. It is widely used in both clinical and preclinical research focused on targeted oncology, immunotherapy, and antibody-drug delivery mechanisms.

Reference

[1]. Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr Hematol Malig Rep. 2020 Feb;15(1):9-19.
[Content Brief]